Ministers meet at Oslo Cancer Cluster
The corona pandemic and international trade were on the top of the agenda when the Foreign Minister of Denmark Jeppe Kofod met with the Minister for Trade, Industry and Fisheries of Norway Iselin Nybø at Oslo Cancer Cluster Innovation Park.
Norway and Denmark are close friends and allies, and the current corona situation has made conversations between Nordic colleagues more valuable than ever.
Export, international trade and investments will be crucial to overcoming the challenges the corona pandemic has brought to Nordic economies.
These pressing issues were discussed when the two ministers from Denmark and Norway met at Oslo Cancer Cluster Innovation Park on 13 August 2020.
The starting point of the meeting was how many companies in the health industry need access to international markets and value chains to grow.
The Norwegian government are preparing an Export Action Plan. It will include several measures to help Norwegian industry come through the corona crisis.
“In the development of the Export Action Plan, the government is collaborating with both industry and financial organisations. We want to gain as much knowledge as possible about where the challenges lie and evaluate which measures are most effective,” Nybø said in a press release from the Department of Trade, Industry and Fisheries.
The Embassy of Denmark in Norway released the following statement after the meeting:
“It is important to attract foreign investments and there is a big potential in Nordic collaboration within the life science sector, since Denmark and Norway have complementary competencies in this field.”
Ketil Widerberg, general manager at Oslo Cancer Cluster, was happy to facilitate the visit and to give input to the ministers on how international collaboration helps the development of cancer treatments:
“Denmark and Norway collaborate on important research areas, including cancer. Our countries have national health data that attract international recognition. Our countries also collaborate on purchasing of developed drugs.
“The opportunity now is the collaboration on how to use our health data and collaborative efforts to better and faster approve new innovative treatments.
“This could reduce development time from 10 to 5 years, and make the Nordics a destination for health innovation.”